Filament Health Corp (OTCQB: FLHLF | NEO: FH) (FSE: 7QS), a clinical‐stage natural psychedelic drug development company, and ATMA Journey Centers, a company focused on delivering effective and innovative experiences that leverage the potential of psychedelic medicine, today announced the recent dosing of 14 healthy subjects with Filament’s natural psilocybin drug candidate in a Health Canada-approved clinical trial as part of ATMA’s psychedelic-assisted therapist training program.

“We are proud to reach this remarkable milestone. The successful dosing of such a large group of subjects, all of whom reported a positive experience, is a testament to the importance of experiential learning and Filament’s psilocybin drug candidate. It also shows promise for our capacity to provide training for therapists and meaningful psychedelic-assisted therapy to patients in need in the future.”

ATMA Chief Executive Officer, David Harder

The trial’s success reflects the operational calibre of both ATMA and Filament.

“Filament’s ability to manufacture and deliver quality-controlled drug candidates sets us apart in the psychedelic industry,” said Filament Health Chief Executive Officer, Benjamin Lightburn. “We have unique expertise in navigating regulatory hurdles which, combined with our in-house GMP manufacturing capabilities, allows us to effectively support partners like ATMA. We look forward to further developing our relationship as they grow their training program.”

Participants weighed in on their experience as part of the trial:

“Being able to experience psilocybin provides a profound impact in being able to support clients through their own experiences. To be able to provide the general public this type of experience, I believe will revolutionize the mental health crisis that we are currently in,” commented a participant named Amber.

“I’ve never experienced anything so magical; the psilocybin kept my physical body in the room but allowed my psyche to travel to another space. A world beyond our eyes. I was the roots of the earth, the mycelium network of the underground. I was able to experience sights and sounds like never before. The integration that has followed has provided me with more insight and learning than anything I could have ever accomplished during my 7 years of antidepressants,” said a participant named Shay.

About Filament Health

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

About ATMA Journey Centers Inc.

ATMA is a Canadian company focused on training and supporting therapists in delivering practical and innovative healing and transformative experiences that leverage the potential of psychedelic medicine to awaken the inner healer and allow a deeper connection with self, with others, and with the beauty of our world. ATMA was the first private company in Canada to conduct legal psychedelic-assisted therapy with psilocybin, one of the active hallucinogens found in ‘magic mushrooms